THANK YOU FOR SUBSCRIBING
FREMONT, CA: "This new funding will allow us to further accelerate product innovation, enabling our customers to continue to bring life-changing medical products and research to market faster. As the market leader for AI-enabled literature review software, the company will further invest in go-to-market initiatives to ensure that the global research community is aware of and can access this important technology." says Peter O'Blenis, CEO of Evidence Partners.
Evidence Partners, one of the industry leaders in AI-enabled literature review automation software and the company behind DistillerSRTM, has closed a $20 million growth financing round, including participation from Thomvest Ventures, Pender Ventures, and Export Development Canada (EDC). Evidence Partners will invest the money to expand internationally and hire more product, engineering, sales, marketing, and customer success personnel.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The foundation of evidence-based research is a literature review, yet producing one has typically been labor-intensive, error-prone, and highly manual. Evidence Partners has been self-funded since its founding in 2008 and, with the creation of DistillerSR, which has had double-digit growth since the platform's launch in 2009, pioneered the development of AI-enabled literature review software. Health policy and clinical practice guidelines, regulatory submissions, and clinical practice guidelines can be improved as more healthcare organizations use DistillerSR to automate their systematic reviews.
"The Evidence Partners team has built an industry-leading product and a global customer base of institutions and enterprises — all without external capital. We are excited to partner with Evidence Partners as they enter their next phase of growth." says Andrew Pinkerton, Partner at Thomvest Ventures.
More in News